{
    "nct_id": "NCT05768139",
    "official_title": "First-in-Human Study of STX-478, a Mutant-Selective PI3Kα Inhibitor as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors",
    "inclusion_criteria": "1. Has an advanced or refractory solid tumor malignancy that is metastatic or locally advanced and unresectable (as specified by Cohort)\n2. Has a new or recent tumor biopsy (collected at screening, if feasible) or archival tumor specimen within 10 years prior to screening\n3. Has a tumor that harbors a documented PI3Kα mutation (cohort specific criterion for cohort-specific mutation types)\n4. Is ≥18 years of age at the time of signing the ICF\n5. Has an ECOG performance status score of 0 or 1 at screening\n6. Has adequate organ function as defined per protocol\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. Has history (within ≤2 years before screening) of a solid tumor or hematological malignancy that is histologically distinct from the cancers being studied\n2. Has symptomatic brain or spinal metastases\n3. Has tumor with known mutations/deletions in PTEN, and activating mutations in AKT (E17K) confirmed by a CLIA-certified or similarly certified laboratory\n4. Has an established diagnosis of diabetes mellitus type 1 or has uncontrolled diabetes mellitus type 2 (based on FPG and HbA1c thresholds defined in the inclusion criteria) requiring antihyperglycemic medication\n5. Cohorts A0, A1, A2, A3, A4, A5 and B: Has had prior treatment with PI3K/AKT/mTOR inhibitor(s), except in certain circumstances\n6. Has had treatment with any local or systemic antineoplastic therapy or investigational anticancer agent within 14 days or 4 half-lives, whichever is longer, prior to the initiation of study treatment up to a maximum washout period of 28 days\n7. Has toxicities from previous anticancer therapies that have not resolved to baseline levels or CTCAE grade ≤1, with the exception of alopecia and peripheral neuropathy\n8. Has had radiotherapy within 14 days before the initiation of study treatment\n9. Cohorts C1, C2, D1, and D2: Any prior systemic therapy for metastatic breast cancer, prior treatment with fulvestrant or any selective estrogen-receptor degrader, with the exception of participants that have received fulvestrant or any selective estrogen-receptor degrader as a part of neoadjuvant therapy only",
    "miscellaneous_criteria": "Key"
}